113. 筋ジストロフィー Muscular dystrophy Clinical trials / Disease details
臨床試験数 : 646 / 薬物数 : 471 - (DrugBank : 105) / 標的遺伝子数 : 59 - 標的パスウェイ数 : 170
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03067831 (ClinicalTrials.gov) | September 2015 | 25/2/2017 | Bone Marrow-Derived Autologous Stem Cells for the Treatment of Duchenne Muscular Dystrophy | Safety and Efficacy of Purified Autologous Bone Marrow-Derived Stem Cell Therapy for Patients With Duchenne Muscular Dystrophy. | Duchenne Muscular Dystrophy | Biological: Stem Cells | Stem Cells Arabia | NULL | Recruiting | 4 Years | 25 Years | All | 20 | Phase 1/Phase 2 | Jordan |
| 2 | NCT02235844 (ClinicalTrials.gov) | September 2014 | 8/9/2014 | Allogeneic Human Umbilical Cord Mesenchymal Stem Cells for a Single Male Patient With Duchenne Muscular Dystrophy (DMD) | Allogeneic Transplantation of Human Umbilical Cord Mesenchymal Stem Cells (UC-MSC) for a Single Male Patient With Duchenne Muscular Dystrophy (DMD) | Duchenne's Muscular Dystrophy | Biological: Umbilical Cord Mesenchymal Stem Cells | Allergy and Asthma Consultants, Wichita, Kansas | Aidan Foundation;Neil H. Riordan PhD | Completed | 28 Years | 31 Years | Male | 1 | Phase 1 | United States |
| 3 | NCT02285673 (ClinicalTrials.gov) | November 2013 | 5/11/2014 | Efficacy of Umbilical Cord Mesenchymal Stem Cells in Duchenne Muscular Dystrophy | Efficacy of Umbilical Cord Mesenchymal Stem Cells in Duchenne Muscular Dystrophy: Phase 1/2 Study | Duchenne Muscular Dystrophy | Biological: Umbilical Cord Mesenchymal Stem Cell | Acibadem University | NULL | Recruiting | 7 Years | 20 Years | Male | 10 | Phase 1/Phase 2 | Turkey |
| 4 | NCT01610440 (ClinicalTrials.gov) | October 2011 | 21/5/2012 | Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Duchenne Muscular Dystrophy | Phase I/II Study of Stem Cell Therapy in Patients With Duchenne Muscular Dystrophy | Duchenne Muscular Dystrophy | Biological: human umbilical cord mesenchymal stem cells | Shenzhen Beike Bio-Technology Co., Ltd. | The Second Affiliated Hospital of Kunming Medical University | Recruiting | 5 Years | 12 Years | Both | 15 | Phase 1/Phase 2 | China |